Tags

Type your tag names separated by a space and hit enter

Glucagon-like peptide 2 inhibits ghrelin secretion in humans.
Regul Pept. 2006 Dec 10; 137(3):173-8.RP

Abstract

INTRODUCTION

The growth hormone secretagogue receptor ligand ghrelin is known to play a pivotal role in the central nervous control of energy homeostasis. Circulating ghrelin levels are high under fasting conditions and decline after meal ingestion, but the mechanisms underlying the postprandial drop in ghrelin levels are poorly understood. In the present study we addressed, whether (1) exogenous GLP-2 administration decreases ghrelin levels and (2) what other endogenous factors are related to ghrelin secretion under fasting conditions.

PATIENTS AND METHODS

Fifteen healthy male volunteers were studied with the intravenous infusion of GLP-2 (2 pmol l(-1) min(-1)) or placebo over 120 min in the fasting state. Plasma concentrations of glucose, insulin, C-peptide, glucagon, intact GLP-2 and ghrelin were determined.

RESULTS

During the infusion of GLP-2, plasma concentrations of intact GLP-2 increased from 10.0+/-1.5 pmol/l to steady-state levels of 207.7+/-8.3 pmol/l (p < 0.0001). Administration of GLP-2 led to an approximately 10% reduction in ghrelin concentrations, whereas placebo administration was without an effect (p < 0.001). After cessation of the GLP-2 infusion, ghrelin levels returned to baseline values, and were no longer different from those in the placebo experiments. There was a strong inverse linear relationship between the fasting concentrations of ghrelin and the respective levels of glucose, insulin and C-peptide (r = 0.49, p < 0.01; r = 0.55, p < 0.01 and r = 0.59, p < 0.001, respectively). In contrast, there was no detectable association between fasting ghrelin levels and the ambient concentrations of glucagon or intact GLP-2.

CONCLUSIONS

GLP-2 inhibits ghrelin secretion in humans at plasma levels of approximately 200 pmol/l. However, the physiological importance of this effect appears to be minor compared to the actions of insulin and glucose.

Authors+Show Affiliations

Department of Medicine I, St. Josef-Hospital, Ruhr-University Bochum, Gudrunstr. 56, 44791 Bochum, Germany.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16928403

Citation

Banasch, Matthias, et al. "Glucagon-like Peptide 2 Inhibits Ghrelin Secretion in Humans." Regulatory Peptides, vol. 137, no. 3, 2006, pp. 173-8.
Banasch M, Bulut K, Hagemann D, et al. Glucagon-like peptide 2 inhibits ghrelin secretion in humans. Regul Pept. 2006;137(3):173-8.
Banasch, M., Bulut, K., Hagemann, D., Schrader, H., Holst, J. J., Schmidt, W. E., & Meier, J. J. (2006). Glucagon-like peptide 2 inhibits ghrelin secretion in humans. Regulatory Peptides, 137(3), 173-8.
Banasch M, et al. Glucagon-like Peptide 2 Inhibits Ghrelin Secretion in Humans. Regul Pept. 2006 Dec 10;137(3):173-8. PubMed PMID: 16928403.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Glucagon-like peptide 2 inhibits ghrelin secretion in humans. AU - Banasch,Matthias, AU - Bulut,Kerem, AU - Hagemann,Dirk, AU - Schrader,Henning, AU - Holst,Jens J, AU - Schmidt,Wolfgang E, AU - Meier,Juris J, Y1 - 2006/08/22/ PY - 2006/06/05/received PY - 2006/06/30/revised PY - 2006/07/20/accepted PY - 2006/8/25/pubmed PY - 2007/3/8/medline PY - 2006/8/25/entrez SP - 173 EP - 8 JF - Regulatory peptides JO - Regul Pept VL - 137 IS - 3 N2 - INTRODUCTION: The growth hormone secretagogue receptor ligand ghrelin is known to play a pivotal role in the central nervous control of energy homeostasis. Circulating ghrelin levels are high under fasting conditions and decline after meal ingestion, but the mechanisms underlying the postprandial drop in ghrelin levels are poorly understood. In the present study we addressed, whether (1) exogenous GLP-2 administration decreases ghrelin levels and (2) what other endogenous factors are related to ghrelin secretion under fasting conditions. PATIENTS AND METHODS: Fifteen healthy male volunteers were studied with the intravenous infusion of GLP-2 (2 pmol l(-1) min(-1)) or placebo over 120 min in the fasting state. Plasma concentrations of glucose, insulin, C-peptide, glucagon, intact GLP-2 and ghrelin were determined. RESULTS: During the infusion of GLP-2, plasma concentrations of intact GLP-2 increased from 10.0+/-1.5 pmol/l to steady-state levels of 207.7+/-8.3 pmol/l (p < 0.0001). Administration of GLP-2 led to an approximately 10% reduction in ghrelin concentrations, whereas placebo administration was without an effect (p < 0.001). After cessation of the GLP-2 infusion, ghrelin levels returned to baseline values, and were no longer different from those in the placebo experiments. There was a strong inverse linear relationship between the fasting concentrations of ghrelin and the respective levels of glucose, insulin and C-peptide (r = 0.49, p < 0.01; r = 0.55, p < 0.01 and r = 0.59, p < 0.001, respectively). In contrast, there was no detectable association between fasting ghrelin levels and the ambient concentrations of glucagon or intact GLP-2. CONCLUSIONS: GLP-2 inhibits ghrelin secretion in humans at plasma levels of approximately 200 pmol/l. However, the physiological importance of this effect appears to be minor compared to the actions of insulin and glucose. SN - 0167-0115 UR - https://www.unboundmedicine.com/medline/citation/16928403/Glucagon_like_peptide_2_inhibits_ghrelin_secretion_in_humans_ DB - PRIME DP - Unbound Medicine ER -